Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Choline bitartrate + betaine is a nutritional intervention consisting of two small molecule nutrients that serve as methyl donors in one-carbon metabolism. Developed by Columbia University for use in research settings, this combination is being evaluated for its ability to enhance the methylation of inorganic arsenic, thereby facilitating its excretion from the body. By increasing the availability of S-adenosylmethionine (SAM), these supplements aim to improve arsenic detoxification in populations chronically exposed to contaminated drinking water, potentially reducing the risk of arsenic-induced health outcomes such as skin lesions, cardiovascular disease, and cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choline bitartrate + betaine.